Robert Butchofsky

Biography

Currently the Chief Executive Officer of Mati Therapeutics, Bob Butchofsky is the former President and CEO of QLT Inc. He served as interim CEO from September of 2005, becoming CEO and a Board member in February 2006 and continuing in that capacity until August 2012. During his tenure as CEO, Mr. Butchofsky modified the company’s strategy and focused the company in ophthalmology resulting in the divestment of non-core assets – generic dermatology business (2006), Aczone (2008), Atrigel (2008), the corporate headquarters building and land (2008) and Eligard (2009). Part of the ocular focused strategy resulted in the acquisition of innovative new technologies including a synthetic retinoid program from Retinagenix for inherited retinal diseases and the punctal plug drug delivery technology from ForSight Labs. Mr Butchofsky was also successful in obtaining US commercial rights for Visudyne from Novartis and launched a US commercial team to promote the brand to ophthalmologists.

Research Interest

Biochemistry